Who are EN3270's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): QUINIDINE, Dextromethorphan HBr, Dextromethorphan Oral Solution, AXS-05, Nuedexta (20/10), diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/en3270.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

EN3270 — Competitive Intelligence Brief

EN3270 (EN3270) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: sigma-1 receptor agonist. Area: Pain.

phase 2 sigma-1 receptor agonist sigma-1 receptor Pain Small molecule Live · refreshed every 30 min

Target snapshot

EN3270 (EN3270) — Durect. EN3270 is a small molecule that targets the sigma-1 receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
EN3270 TARGET	EN3270	Durect	phase 2	sigma-1 receptor agonist	sigma-1 receptor
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Dextromethorphan HBr	Dextromethorphan HBr	Galera Therapeutics, Inc.	marketed	NMDA receptor antagonist; sigma-1 receptor agonist	NMDA receptor; sigma-1 receptor
Dextromethorphan Oral Solution	Dextromethorphan Oral Solution	Helsinki University Central Hospital	marketed	Non-opioid antitussive	NMDA receptor antagonist; sigma-1 receptor
AXS-05	AXS-05	Axsome Therapeutics, Inc.	marketed	Combination antidepressant (NMDA antagonist + norepinephrine-dopamine reuptake inhibitor)	Sigma-1 receptor, NMDA receptor, norepinephrine transporter, dopamine transporter
Nuedexta (20/10)	Nuedexta (20/10)	St. Joseph's Hospital and Medical Center, Phoenix	marketed	Sigma-1 receptor agonist combination	Sigma-1 receptor
diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan	Montefiore Medical Center	marketed	Combination cold/cough/allergy remedy	H1 histamine receptor (diphenhydramine); alpha-1 adrenergic receptor (phenylephrine); NMDA receptor and sigma-1 receptor (dextromethorphan)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (sigma-1 receptor agonist class)

Anavex Life Sciences Corp. · 1 drug in this class
Durect · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EN3270 — Competitive Intelligence Brief. https://druglandscape.com/ci/en3270. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab